死亡率宣言：抑肽酶与氨甲环酸死亡率的荟萃分析 - Suppr | 超能文献

Mortality manifesto: a meta-analysis of aprotinin and tranexamic acid mortality.

作者信息

Brown Jeremiah R

出版信息

Eur J Cardiothorac Surg. 2009 Oct;36(4):781-2. doi: 10.1016/j.ejcts.2009.06.014. Epub 2009 Jul 18.

DOI:10.1016/j.ejcts.2009.06.014

Abstract

摘要

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

文档翻译

学术文献翻译模型，支持多种主流文档格式。

相似文献

1

Mortality manifesto: a meta-analysis of aprotinin and tranexamic acid mortality.死亡率宣言：抑肽酶与氨甲环酸死亡率的荟萃分析

Eur J Cardiothorac Surg. 2009 Oct;36(4):781-2. doi: 10.1016/j.ejcts.2009.06.014. Epub 2009 Jul 18.

2

Aprotinin increases mortality as compared with tranexamic acid in cardiac surgery: a meta-analysis of randomized head-to-head trials.与氨甲环酸相比，抑肽酶增加心脏手术死亡率：随机头对头试验的荟萃分析。

Interact Cardiovasc Thorac Surg. 2009 Jul;9(1):98-101. doi: 10.1510/icvts.2008.198325. Epub 2009 Apr 20.

3

Lessons from aprotinin: is the routine use and inconsistent dosing of tranexamic acid prudent? Meta-analysis of randomised and large matched observational studies.抑肽酶的教训：常规使用和剂量不一致的氨甲环酸是否合理？随机对照研究和大型匹配观察性研究的荟萃分析。

Eur J Cardiothorac Surg. 2010 Jun;37(6):1375-83. doi: 10.1016/j.ejcts.2009.11.055. Epub 2010 Feb 1.

4

eComment: A comparison of the safety of aprotinin and tranexamic acid in cardiac surgery.电子评论：抑肽酶与氨甲环酸在心脏手术中的安全性比较

Interact Cardiovasc Thorac Surg. 2009 Jul;9(1):101. doi: 10.1510/icvts.2008.198325A.

5

Tranexamic acid and aprotinin in low- and intermediate-risk cardiac surgery: a non-sponsored, double-blind, randomised, placebo-controlled trial.氨甲环酸与抑肽酶用于低危和中危心脏手术：一项非赞助的、双盲、随机、安慰剂对照试验。

Eur J Cardiothorac Surg. 2009 Aug;36(2):322-9. doi: 10.1016/j.ejcts.2008.11.038. Epub 2009 Feb 27.

6

The blood sparing effect and the safety of aprotinin compared to tranexamic acid in paediatric cardiac surgery.小儿心脏手术中抑肽酶与氨甲环酸相比的血液保护作用及安全性

Eur J Cardiothorac Surg. 2009 Jan;35(1):167-71; author reply 171. doi: 10.1016/j.ejcts.2008.09.038. Epub 2008 Nov 21.

7

The risks of aprotinin and tranexamic acid in cardiac surgery: a one-year follow-up of 1188 consecutive patients.抑肽酶和氨甲环酸在心脏手术中的风险：对1188例连续患者的一年随访

Anesth Analg. 2008 Dec;107(6):1783-90. doi: 10.1213/ane.0b013e318184bc20.

8

Antifibrinolytics.抗纤维蛋白溶解剂

Acta Anaesthesiol Belg. 2003;54(4):319-22.

9

Aprotinin, but not tranexamic acid, is associated with increased pulmonary microvascular fibrin deposition after cardiac surgery.

Thromb Res. 2011 Mar;127(3):272-4. doi: 10.1016/j.thromres.2010.11.014. Epub 2010 Dec 22.

10

The safety and efficacy of antifibrinolytic therapy in neonatal cardiac surgery.抗纤溶疗法在新生儿心脏手术中的安全性和有效性。

PLoS One. 2015 May 8;10(5):e0126514. doi: 10.1371/journal.pone.0126514. eCollection 2015.

引用本文的文献

1

Regulatory decisions pertaining to aprotinin may be putting patients at risk.与抑肽酶相关的监管决策可能会使患者处于风险之中。

CMAJ. 2014 Dec 9;186(18):1379-86. doi: 10.1503/cmaj.131582. Epub 2014 Sep 29.